Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta‐analysis

• Published in: British journal of clinical pharmacology 2022-05, Vol.88 (5), p.1985-1998
• Main Authors: Samura, Masaru, Takada, Keisuke, Hirose, Naoki, Kurata, Takenori, Nagumo, Fumio, Koshioka, Sakura, Ishii, Junichi, Uchida, Masaki, Inoue, Junki, Enoki, Yuki, Taguchi, Kazuaki, Tanikawa, Koji, Matsumoto, Kazuaki
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - adverse effects; concomitant use; Creatine Kinase; creatine phosphokinase elevation; daptomycin; Daptomycin - adverse effects; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Incidence; meta‐analysis; Retrospective Studies; Rhabdomyolysis - chemically induced; Rhabdomyolysis - epidemiology; statin
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/bcp.15172

Aims The present systematic review and meta‐analysis evaluated the incidence of elevated creatine phosphokinase (CPK) levels between daptomycin alone and concomitant daptomycin and statin use. Methods We searched the PubMed, Web of Sciences, Cochrane Library and ClinicalTrials.gov databases. We analysed the incidence of elevated CPK between daptomycin alone and concomitant daptomycin and statins among studies defining CPK elevation as levels ≥ the upper limit of normal (ULN) or ≥5× ULN. We also analysed the incidence of rhabdomyolysis between the groups. We then calculated the odds ratios (ORs) and 95% confidence intervals (CIs) based on the included studies. Results Comparing CPK elevation defined as CPK levels ≥ULN, a significantly higher incidence of CPK elevation was observed with concomitant daptomycin and statin use than with daptomycin alone (OR = 2.55, 95% CI 1.78–3.64, P